Helicos BioSciences Corporation

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock

February 28, 2007

CAMBRIDGE, MASS., February 28 /CNW/ - Helicos BioSciences Corporation today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold in the proposed offering and the offering price have not yet been determined.

Mascoma Corporation

Royal Nedalco Signs Agreement to License Technology to Mascoma for Lignocellulosic Ethanol

Royal Nedalco Signs Agreement to License Technology to Mascoma for Lignocellulosic Ethanol

March 2, 2007

American – Dutch Technology Partnership to Explore Collaborative Research to Accelerate Commercialization of Lignocellulosic Ethanol

VisEn Medical, Inc.

VisEn Medical Announces Initiative with Merck to Develop Molecular Imaging Agents for Key Areas in Cardiovascular Disease

VisEn Medical Announces Initiative with Merck to Develop Molecular Imaging Agents for Key Areas in Cardiovascular Disease

March 6, 2007

Woburn, MA -- March 6, 2007 –VisEn Medical today announced the launch of a multi-year joint research and development program with Merck & Co., Inc. to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo.

LS9

Renewable Petroleum Company LS9 Announces Series A Funding and Scientific Advisory Board Members

Renewable Petroleum Company LS9 Announces Series A Funding and Scientific Advisory Board Members

March 12, 2007

Company Positioned for Biofuel Breakthroughs and Commercialization

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel™

Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel™

March 19, 2007

Pioneer in regenerative cell-based therapies and devices kicks off patient recruitment for Phase II clinical safety trials of first biologically-active treatment to ameliorate acute vascular injury in multiple disease states

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has begun enrolling patients in two Phase II clinical trials of the company’s first product, Vascugel™.

Mascoma Corporation

Mascoma Corporation Names Ethanol Executive Bruce A. Jamerson as Chief Executive Officer

Mascoma Corporation Names Ethanol Executive Bruce A. Jamerson as Chief Executive Officer

March 19, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in cellulosic biomass-to-biofuels development and production, today announced the appointment of Bruce A. Jamerson as its Chief Executive Officer and member of the Board of Directors. He was previously President of VeraSun Energy Corporation, a leading ethanol producer based in Brookings, South Dakota. Mr. Jamerson will apply his experience in ethanol, energy and finance to the company’s strategic initiatives and operations.

Morphotek, Inc.

Eisai to Acquire Morphotek

Eisai to Acquire Morphotek

March 22, 2007

Eisai’s Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition

Selventa

Genstruct Appoints VP of Scientific Research

Genstruct Appoints VP of Scientific Research

March 26, 2007

CAMBRIDGE, Mass., March 26, 2007 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced the appointment of Christian Reich, M.D., Ph.D. to vice president of Scientific Research. In this position, Dr. Reich will lead Genstruct's internal biology research teams as well as efforts in translational medicine and clinical research in partnership with its large pharmaceutical partners, which include GSK and Pfizer.

Mascoma Corporation

Mascoma Secures $4.9MM Funding from U.S. Department of Energy

Mascoma Secures $4.9MM Funding from U.S. Department of Energy

March 28, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in cellulosic biomass-to-biofuels development and production, today announced it has secured $4.9 million in funding from the U.S. Department of Energy (DOE). The funding is specifically for the development of fermentative organisms that speed the conversion of cellulosic biomass into ethanol, making it commercially viable to produce. Mascoma will utilize the funds for a joint project with the Oak Ridge National Laboratory in Tennessee, the DOE’s largest science and energy laboratory.

Acceleron Pharma, Inc.

Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing

Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing

March 29, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 29, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced the appointment of Robert Steininger as Senior Vice President, Manufacturing.